Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Equillium Inc (EQ)
Equillium Inc (EQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,063
  • Shares Outstanding, K 34,569
  • Annual Sales, $ 15,760 K
  • Annual Income, $ -62,430 K
  • 60-Month Beta 1.22
  • Price/Sales 1.58
  • Price/Cash Flow N/A
  • Price/Book 0.96
Trade EQ with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.53
  • Most Recent Earnings -0.10 on 08/09/23
  • Next Earnings Date 11/13/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 394.12% ( -94.56%)
  • Historical Volatility 35.32%
  • IV Percentile 73%
  • IV Rank 32.26%
  • IV High 1,085.67% on 07/25/23
  • IV Low 64.81% on 11/01/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 412
  • Open Int (30-Day) 414

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.16
  • Number of Estimates 4
  • High Estimate -0.09
  • Low Estimate -0.27
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7200 +0.83%
on 09/27/23
0.8727 -16.81%
on 09/05/23
-0.0986 (-11.96%)
since 08/28/23
3-Month
0.6871 +5.66%
on 07/25/23
0.9399 -22.76%
on 07/10/23
+0.0049 (+0.68%)
since 06/28/23
52-Week
0.4783 +51.79%
on 05/09/23
2.3400 -68.97%
on 10/03/22
-1.5040 (-67.44%)
since 09/28/22

Most Recent Stories

More News
3 Brilliant Biotech Stocks to Buy for Your Portfolio

The biotech industry is flourishing on the backs of positive clinical trials and new developments. Thus, it could be beneficial to add fundamentally robust biotech stocks BioMarin Pharmaceutical (BMRN),...

BMRN : 89.25 (-1.24%)
EQ : 0.7260 (+0.14%)
ORGO : 3.39 (+27.92%)
Top 3 Biotech Stocks to Watch and Buy for Healthy Profits

With innovative approaches and cutting-edge technologies, biotech has ushered in a new era of possibilities in the medical field. Hence, investing in three fundamentally sound biotech stocks, Equillium,...

EQ : 0.7260 (+0.14%)
EXEL : 22.39 (+0.90%)
THTX : 2.18 (+1.40%)
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders...

EQ : 0.7260 (+0.14%)
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders...

EQ : 0.7260 (+0.14%)
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 0.7260 (+0.14%)
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation...

EQ : 0.7260 (+0.14%)
Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 0.7260 (+0.14%)
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was...

EQ : 0.7260 (+0.14%)
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.

EQ : 0.7260 (+0.14%)
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited,...

EQ : 0.7260 (+0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 0.8007
2nd Resistance Point 0.7853
1st Resistance Point 0.7557
Last Price 0.7260
1st Support Level 0.7107
2nd Support Level 0.6953
3rd Support Level 0.6657

See More

52-Week High 2.3400
Fibonacci 61.8% 1.6288
Fibonacci 50% 1.4092
Fibonacci 38.2% 1.1895
Last Price 0.7260
52-Week Low 0.4783

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar